Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer

MLA

Biagio Ricciuti, et al. “Multi-Institutional Analysis of Aneuploidy and Outcomes to Chemoradiation and Durvalumab in Stage III Non-Small Cell Lung Cancer.” Journal for ImmunoTherapy of Cancer, vol. 11, no. 11, Nov. 2023. EBSCOhost, https://doi.org/10.1136/jitc-2023-007618.

APA

Biagio Ricciuti, Joao V Alessi, Mark M Awad, Arielle Elkrief, Jamie E Chaft, Bruce E Johnson, Xinan Wang, Allison L Richards, Federica Pecci, Alessandro Di Federico, Adam J Schoenfeld, Malini M Gandhi, Adam Price, Emily S Lebow, Patricia Mae G Santos, Maria Thor, Andreas Rimner, Daniel R Gomez, & Narek Shaverdian. (2023). Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer. Journal for ImmunoTherapy of Cancer, 11(11). https://doi.org/10.1136/jitc-2023-007618

Chicago

Biagio Ricciuti, Joao V Alessi, Mark M Awad, Arielle Elkrief, Jamie E Chaft, Bruce E Johnson, Xinan Wang, et al. 2023. “Multi-Institutional Analysis of Aneuploidy and Outcomes to Chemoradiation and Durvalumab in Stage III Non-Small Cell Lung Cancer.” Journal for ImmunoTherapy of Cancer 11 (11). doi:10.1136/jitc-2023-007618.